Romidepsin is a natural cyclic depsipeptide that functions as a potent histone deacetylase inhibitor. It is approved for treating certain lymphomas and studied for its antiproliferative effects in cancer research.
In the literature, Romidepsin appears most often in work focused on cancer research. Studies in this area tend to look at mechanisms and observed effects in laboratory and preclinical settings rather than outcomes in people, so the picture is best read as a map of where researchers have been curious — not as evidence of any benefit.
Romidepsin is catalogued here under powder peptides. Coverage of this compound varies in quality and depth, and much of it remains early-stage. Reading the underlying research directly is the only way to judge how strong any particular finding is.
Tap a topic to see which peptides are most studied for it.
Abarelix is a synthetic GnRH antagonist that was approved for treating advanced prostate cancer. It was studied for its ability to suppress hormone production to manage certain cancers.
Buserelin is a synthetic GnRH agonist analog used clinically for hormone-sensitive conditions. Researchers study its effects on hormone regulation for conditions like prostate cancer, endometriosis, and fertility treatments.
Lutetium-177 Dotatate is an FDA-approved radiopharmaceutical for treating somatostatin receptor-positive neuroendocrine tumors. It delivers targeted radiation to cancer cells.
Research use only. This page summarizes areas of published study and is not medical advice. No dosing, protocol, or usage guidance is provided.